HIV: treatment as prevention working

A record high of more than 90% of HIV-positive gay and bisexual men are achieving an undetectable viral load thanks to antiretroviral treatment

UNSW researchers have recorded an “encouraging” major shift towards newer forms of prevention of HIV transmission, thanks to government-funded access programs.

The researchers, from the university’s Centre for Social Research in Health (CSRH) say 92% of HIV-positive gay and bisexual men are taking antiretroviral treatment and achieving an undetectable viral load.

The result is more than 90% of these men can no longer transmit HIV. This is a record high for the third year running.

The Annual Report of Trends in Behaviour 2018 was released by the CSRH at UNSW Sydney, alongside The Kirby Institute’s Annual Surveillance Report in HIV, viral hepatitis and sexually transmissible infections in Australia at the Australasian HIV/AIDS Conference in Sydney.

The report finds the proportion of gay men with casual partners who reported using the HIV prevention tool pre-exposure prophylaxis (PrEP) before sex increased from 1% in 2013 to 5% in 2016 and then to 16% in 2017.

Project leader of the Gay Community Periodic Surveys at CSRH, Professor Martin Holt, said this increase was mostly seen during 2016-2017.

He says this suggests that PrEP uptake was boosted by access to state-funded PrEP programs in NSW, Victoria and Queensland in 2016.

“PrEP and treatment as prevention (TasP) are becoming increasingly popular HIV prevention strategies used by gay and bisexual men, particularly those well connected to the urban gay community networks,” Professor Holt said.

Scroll to Top

During the Canada Post strike announced September 25, 2025, the following measures will be undertaken to minimize service disruption to BC-CfE clients and providers.

  • The BC-CfE Laboratory has transitioned to private courier for delivery of outgoing reports and documents. Results required urgently can be faxed upon request. (Lab Contact Information: Phone 604-806-8775; FAX 604-806-9463)
  • The BC-CfE Drug Treatment Program (DTP) will fax outgoing forms and documents to the provider’s office. (DTP Contact Information: Phone 604-806-8515; FAX 604-806-9044)
  • St. Paul’s Hospital Ambulatory Pharmacy has transitioned to private courier for delivery of medications. We recommend requesting medication at least 2 weeks in advance in case of delivery delays, particularly to rural/remote parts of BC. (Contact Information: Phone 1-800-547-3622; FAX 604-806-8675)

During the Canada Post strike, we recommend that documents be faxed or couriered to our sites, versus utilization of regular mail service

The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below